Statins can safely cut risk of heart attacks or strokes in healthy people aged over 70, world-first clinical trial shows

A world-first clinical trial has demonstrated that statins can safely reduce the risk of strokes and heart attacks in healthy individuals aged 70 and older. This specific study, known as the STAREE trial, focused on older adults who had no prior history of cardiovascular disease (CVD). According to data reported by Medscape and TCTMD.com, the use of atorvastatin resulted in a 30% reduction in major adverse cardiovascular events (MACE). Medscape further specifies that this reduction was primarily driven by a decrease in nonfatal events among the participants. Coverage of these findings is widespread across medical and general news outlets.

The Guardian reports on the trial's ability to cut risks for healthy seniors, while SMH.com.au describes the medication as a common treatment that lowers heart attack risks in older populations. Specialized outlets like TCTMD.com and Medscape provide the technical specifics of the STAREE trial, highlighting the 30% drop in major cardiovascular events. These reports emphasize that the benefit was observed even in those without a preexisting history of cardiovascular disease. Beyond immediate cardiovascular benefits, other reports suggest a link between statins and cognitive health. The Guardian reports on a long-term study suggesting that statins can reduce the risk of dementia by up to 15%.

Additionally, Medical Xpress notes that the early initiation of statins following a diagnosis of type 2 diabetes is associated with a lower risk of developing dementia. These findings provide a broader context for the use of statins in aging populations, extending the potential benefits from heart health to neurological protection. Future attention will likely focus on the long-term application of the STAREE trial results for the elderly. Because the trial is described as a world-first, the medical community will be monitoring how these findings influence prescribing habits for healthy adults over 70. The intersection of statin use, type 2 diabetes, and dementia risk will also remain a point of interest following the data provided by Medical Xpress and The Guardian regarding cognitive decline.